Review

Pathophysiology of Depression: Stingless Bee Honey Promising as an Antidepressant

Fatin Haniza Zakaria 1, Ismail Samhani 2, Mohd Zulkifli Mustafa 1,* and Nazlahshaniza Shafin 3,*

1 Department of Neuroscience, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, Kota Bharu 16150, Malaysia
2 Faculty of Medicine, Universiti Sultan Zainal Abidin (UniSZA), Medical Campus, Jalan Sultan Mahmud, Kuala Terengganu 20400, Malaysia
3 Department of Physiology, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, Kota Bharu 16150, Malaysia
* Correspondence: zulkifli.mustafa@usm.my (M.Z.M.); drshaniza@usm.my (N.S.); Tel.: +609-7673000 (M.Z.M. & N.S.)

Abstract: Depression is a debilitating psychiatric disorder impacting an individual’s quality of life. It is the most prevalent mental illness across all age categories, incurring huge socio-economic impacts. Most depression treatments currently focus on the elevation of neurotransmitters according to the monoamine hypothesis. Conventional treatments include tricyclic antidepressants (TCAs), norepinephrine–dopamine reuptake inhibitors (NDRIs), monoamine oxidase inhibitors (MAOIs), and serotonin reuptake inhibitors (SSRIs). Despite numerous pharmacological strategies utilising conventional drugs, the discovery of alternative medicines from natural products is a must for safer and beneficial brain supplement. About 30% of patients have been reported to show resistance to drug treatments coupled with functional impairment, poor quality of life, and suicidal ideation with a high relapse rate. Hence, there is an urgency for novel discoveries of safer and highly effective depression treatments. Stingless bee honey (SBH) has been proven to contain a high level of antioxidants compared to other types of honey. This is a comprehensive review of the potential use of SBH as a new candidate for antidepressants from the perspective of the monoamine, inflammatory and neurotrophin hypotheses.

Keywords: depression; inflammation; monoamine; neurotrophin; stingless bee honey

1. Revisiting Depression

Depression is a psychiatric disorder characterized by psychological, behavioral and physiological symptoms that include a persistent low mood, marked loss of pleasure in most activities, poor concentration, disruptions in appetite and sleeping patterns, cognitive impairments, feelings of worthlessness, excessive guilt, and suicidal thoughts [1]. It is the leading cause of disability worldwide that poses a high emotional and financial burden [2,3]. The World Health Organization (WHO) estimated that depression will be declared a global burden by the year 2030 [4] affecting an estimation of 300 million people from all age categories [5].

Depression covers various subtypes and etiologies [6] from monoamines to inflammatory and neurotrophic propositions. In the 1960s, the “catecholamine hypothesis” appeared as a popular monoamine hypothesis for explaining depression development. It suggested that serotonin (5HT) deficiency and noradrenaline (NA) creates depression [7–9]. The inflammatory hypothesis proposes that depression is caused by the interaction of inflammatory cytokine with the hypothalamic–pituitary–adrenal (HPA) axis, consequently affecting the synthesis and reuptake of neurotransmitters [10,11], which subsequently triggers glucocorticoid resistance, glutamate excitotoxicity, and the reduction of brain-derived neurotrophic factor (BDNF) expression [12].
Since BDNF is reduced in the onset of depression, the neurotrophic hypothesis has become one of the critical etiologies of antidepressant progression. This hypothesis states that neurotrophic factors are essential to the development of neurons by promoting synaptic growth and maintaining neuronal survival. They play a crucial role in neuronal network formation and plasticity. On the contrary, the reduction of neurotrophic factors is implicated in the atrophy of stress-vulnerable hippocampal neurons, such as depression and cognitive disorder [13]. This deficiency is believed to be reversed by antidepressant treatments that contribute to the resolution of depressive symptoms [14].

Since the number of depression cases is increasing day by day, the discovery of new treatments is imperative. At present, there is a vibrant demand for new treatment strategies since the flaws of conventional treatments are striking. For instance, many sources purport that antidepressants have a therapeutic delay onset, taking weeks rather than days to become effective [15,16]. Prolonged exposure to antidepressant drugs imposes susceptibility to adverse side effects, such as interferences in sexual functioning, gastrointestinal disturbances, altered sleep pattern, and weight gain [17–22]. Moreover, 30% of patients have been reported to be non-compliant with currently available treatments [23–25]. Thus, there is a dire need for the development of new antidepressant treatments with better efficacy and that are safer for patients [26].

This has caused an urgent call for complementary and alternative medicines in treating depression [27]. Honey, which contains a variety of active compounds beneficial to brain regulation and treats emotional and psychological disorders including depression [28–30] is one of the natural products serving as an alternative medicine [31]. Among the various types of honey, here we focus on stingless bee honey (SBH). In Malaysia, SBH is well known as “madu kelulut” [32]. In addition to SBH, there are other honeys capable of treating several health problems named Tualang and Manuka [33,34]. However, in terms of nutritional composition, SBH contains a higher level of polyphenol [35–37], an important active compound that participates in modulating signaling pathways, thus influencing neuronal survival and cell regeneration and development, which suffer detrimental effects after injury [38,39]. To date, there are limited studies highlighting the potential of SBH as an alternative supplement to treat depression. Therefore, this review discusses the different hypotheses associated with depression and how SBH’s mechanism of action could act as a potential antidepressant as a brain supplement. We highlight the different types of etiology hypotheses in the pathophysiology of depression followed by its mechanism of action.

2. Pathophysiology of Depression
2.1. Monoamine Hypothesis
Depression is a well-known psychiatric disorder that involves the dysregulation of the monoamine system that leads to an imbalance of neurotransmitters, such as 5HT, dopamine, and NA [40,41]. Monoamines are molecules involved in information transmission processes by connecting presynaptic to postsynaptic neurons [42]. They are classified according to their chemical structure and mechanism of action [43]. Since they have different chemical structures, every monoamine is specific to its respective receptors [42] and has a different function in the brain [40,44,45]. For example, 5HT is a central nervous system monoamine that has a crucial role in regulating appetite, circadian cycle, anxiety, memory, and learning. In addition to 5HT, dopamine is another important monoamine that fuels motivation and modulates pleasure, reward, and emotion. In addition, NA is another essential monoamine responsible for attentiveness, emotions, cognition, and social interactions.

The monoamine hypothesis was formulated in the mid-1960s due to the underactivity of brain monoamines such as serotonin, dopamine, and NA in patients’ brains [46]. This hypothesis is based on antidepressant drug efficacy, such as selective serotonin reuptake inhibitors (SSRIs), norepinephrine–dopamine reuptake inhibitors (NDRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) [47,48]. The mechanisms of action for this hypothesis with antidepressants are: (1) inhibition of the reuptake of 5HT and/or NA; (2) antagonistic presynaptic inhibition of 5HT and/or NA; and (3) inhibition
of monoamine oxidase (MAO) [45]. Findings on these mechanisms of action showed that chronic treatment with antidepressants ultimately causes increased levels of monoamines.

Apart from 5HT, dopamine, and NA, γ-aminobutyric acid (GABA) is also reported to affect depression [49–52]. GABA plays a role in depression and anxiety through its interaction with inflammatory cytokines, NF-κB, and p38 MAPK signaling pathways [53].

2.2. Inflammation Hypothesis in Depression

The inflammation theory has also been linked to depression, which surprises many people. It acts as a key point regarding treatment direction for depression cases. Believed to be fueled by lifestyle, the inflammatory process is related to the nuclear factor-κB (NF-κB) pathway [54], a transcriptional factor that regulates various gene expressions. It is activated by extracellular stimuli, such as lipopolysaccharide (LPS), administration, or chronic stress [55–58], giving it a propensity to go haywire. Once it is activated, an inflammatory response takes place [59,60].

An inflammatory response includes the secretion of cytokines, which have a specific effect on the interactions and communications between cells [61]. Cytokines are signaling proteins secreted in response to the immune system’s activation by stressors, such as injury, infection, or psychosocial factors [62]. Moreover, the cytokines induce anti- or pro-inflammatory responses, whereby the anti-inflammatory cytokines are secreted to counteract the pro-inflammatory cytokines [63,64]. Cytokines comprise lymphokine (cytokine made by lymphocytes), monokine (cytokine made by monocytes), chemokine (cytokines with chemotactic activities), and interleukin (cytokines made by one leukocyte and acting on other leukocytes). Part of them is recognized as IL-2, IFN-γ, IL-1β, TNF-α, IL-6, IL-12, IL-15 for pro-inflammatory functions [65–67] and as IL-4, IL-5, IL-13, IL-1Ra, IL-10 for anti-inflammatory action [68].

Inflammatory responses play a primary role in eliminating or inactivating harmful entities or damaged tissues in the body. However, the over-activation of this system can cause detrimental effects, such as depressive-like behavior [69,70]. Previous studies have shown that depressed people have increased levels of inflammatory mediators, such as C-reactive protein (CRP) and pro-inflammatory cytokines [71,72]. In response to inflammation, the translocation of inflammatory mediators interferes with neuronal and glial well-being, resulting in cognitive and behavioral manifestations, and synaptic plasticity that leads to neurodegeneration [73].

There are two major pathways for inflammatory cytokines that disrupt the synthesis of monoamine neurotransmitters, particularly 5HT, glutamate, and dopamine, as shown in Figure 1.

They are important for neurotransmitter regulation and ultimately affect mood regulation in depression, namely kynurenine and tetrahydrobiopterin (BH4) [66,74,75]. Activation of the kynurenine pathway (KP) within areas of the brain, such as the hippocampus, has been shown to cause alterations in emotional behaviors [76–78]. This is because KP affects the most important neurotransmitter for the regulation of emotion, which is 5HT [79]. When inflammation occurs, levels of indoleamine 2, 3-dioxygenase (IDO) and tryptophan 2, 3-dioxygenase (TDO) are elevated and the tryptophan is used by the IDO and TDO in kynurenine production [80]. This eventually causes the depletion of the tryptophan level for 5HT production. This has been proven in animal models and drug therapy patients with interferon-α [81,82]. IDO and TDO are induced by pro-inflammatory cytokines, such as IL-1, IL-2, IL-6 and IFN-γ [80]. KP causes the increased production of several harmful metabolites, such as 3-hydroxykynurenine (3HK) and quinolinic acid (QA), causing the over-activation of the N-methyl-D-aspartate (NMDA) receptor and inducing oxidative stress and kynurenic acid [83]. The link between inflammation and KP is evident through the increased number of astrocytes that are synthesized by kynurenine acid and the increased production of quinolinic acid by microglia [79]. Alongside kynurenine, the tetrahydrobiopterin (BH4) pathway is also significant due to the monoamine neurotransmitter synthesis that is disrupted in depression [67]. Analyzed SBH sample identified
compounds such as phenylalanine, alanine, tyrosine, valine, acetate, lactate, trigonelline, ethanol metabolites, glucose, fructose, sucrose, and maltose [84]. Phenylalanine, which is consistently found in SBH, converted to tyrosine, which simultaneously converts BH4 to 4a-Hydroxytetrahydrobiopterin and is catalyzed by phenylalanine hydroxylase [85]. BH4 is a cofactor for precursors of neurotransmitters, namely 5HT, dopamine, and NA [75]. For example, the serotonergic pathway biosynthesis of 5HT comes from tryptophan, whereas dopaminergic, noradrenergic, and adrenergic pathways are intermediated by the precursor L-3,4-dihydroxyphenylalanine (L-DOPA) for the synthesis of dopamine, adrenaline, and NA [86,87]. Inflammatory cytokines can disrupt BH4 production, which is crucial for neurotransmitter synthesis [67]. There are two mechanisms that are involved in the disruption of BH4. Firstly, inflammatory cytokines stimulate NOS to produce NO. The elevated activity of NOS causes the increased utilization of BH4 that will be converted to 7, 8-dihydrobiopterin (BH2).

![Figure 1. Summary of the mechanism of action for inflammation leading to depression.](image)

The conversion of arginine to nitric oxide (NO) by nitric oxide synthase (NOS) is enhanced by BH4, which acts as an enzyme co-factor [88]. Furthermore, BH4 is very sensitive to oxidative stress. Inflammatory cytokines are known to increase oxidative stress through the production of both nitrogen and oxygen-free radicals. This causes the irreversible degradation of BH4 to dihydroxyanthopterin [89].

2.3. Neurotrophin Hypothesis

In addition to the monoamine and inflammatory hypothesis, the neurotrophin hypothesis also has a vital role in the pathophysiology of depression [90]. Neurotrophin is a type of protein that is essential for the growth, survival, and differentiation of neurons [91,92]. Four types of neurotrophins are important in mammals, namely brain-derived neurotrophin factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) [93]. BDNF is critical in the central nervous system (CNS) for neurogenesis, synaptic plasticity, development, survival, and neuron maintenance [94–97]. BDNF is an example of a neurotrophin that has an impact on the pathophysiology of depression [13,97,98]. BDNF and its receptor tropomyosin receptor kinase B (TrKB) are involved in different intracellular signaling pathways, such as mitogen-activated protein kinase/extracellular signal-regulated protein kinase (MAPK/ERK), phospholipase Cγ (PLCγ), and phospho-
inositide 3-kinase (PI3K) [99]. These pathways have a biological impact on the central nervous system, such as on memory and mood regulation [95,100,101]. ERK is one of the downstream BDNF pathways that is implicated in the regulation of mood and behavior in the depression model that mediates the effects of antidepressants [102–105]. Meanwhile, PI3K signaling is an important component of long-term potentiation (LTP) [106]. This signaling pathway acts as a biochemical cascade for α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) for synaptic plasticity, thus causing behavioral alteration [107]. Moreover, all the intracellular signaling pathways that were mentioned earlier have been discussed in previous studies that are related to depression. Changes in BDNF levels in the central nervous system disrupt the entire signaling pathway, which can lead to various psychological disorders, including depression [108–112].

BDNF promotes neurogenesis, which is part of neuroplasticity. Neuroplasticity involves changes or alterations in the structure, functions, and connections of the central nervous system (CNS) in response to intrinsic or extrinsic stimuli [113]. These changes include the morphology of mature neurons, such as axonal and dendritic arborization and pruning, increased spine density, and synaptogenesis [114]. Neurogenesis is defined as the formation of newborn neurons in proliferative areas that include the subventricular zone (SVZ) and the subgranular zone (SGZ) of the dentate gyrus region in the hippocampus area [114,115]. This region is crucial for memory, learning, and other cognitive functions [116]. The alteration of BDNF levels is known to be detrimental to neurogenesis in the hippocampus, specifically in the dentate gyrus region [117]. The dentate gyrus is a region in the hippocampus that is widely discussed in depression [118–120]. Based on previous studies, BDNF levels in the hippocampus and prefrontal cortex are reduced in cases of depression [13,121,122]. This consequently resulted in the decreased size of the hippocampal area in the brain in both clinical and preclinical studies of depression [118–120]. Similarly, the condition is observed in the prefrontal cortex [118,123,124] causing neuronal loss and synaptic dysfunction in cortical limbic regions that ultimately disrupt mood and emotions [73].

In addition to neurogenesis as a part of neuroplasticity related to BDNF in the brain, synaptic plasticity is also associated with depression [41,125,126]. Synaptic plasticity is essential for the physiological morphology of neurons, and BDNF is one of the crucial regulators in this process making it a therapeutic target in depression [127]. Therefore, the BDNF level is vulnerable to synaptic plasticity in the brain. Long-term potentiation (LTP) is the main mechanism that mediates neuroplasticity at a functional level; synaptic strength is crucial for the connection between neurons in the brain [113]. BDNF facilitated LTP in the Schaffer collaterals of the hippocampus in a young animal model by inducing the release of presynaptic neurotransmitters [128]. Furthermore, the postsynaptic release of BDNF induces LTP in the dentate gyrus [129]. Increased hippocampal dendritic spine by LTP is contributed by BDNF signaling together with local protein translation [130]. Based on previous studies, patients showed decreased hippocampal volume and BDNF expression during depressive episodes compared to patients in remission, which altered synaptic plasticity by elevating hippocampal dendritic atrophy and cell death contributing to the decline of LTP [122,131,132]. These features have also been observed in rodents [133–135]. Moreover, the reduction of LTP caused by depression has been observed especially in the hippocampus and the prefrontal brain area [73,136,137]. The same effect has been observed in long-term depression (LTD) [138].

3. Stingless Bee Honey (SBH) as an Antidepressant

Earlier in this review, the etiology of pathological depression was discussed briefly. In this section, the role of SBH as a prophylactic against depression is reviewed. The focus will be on certain properties of SBH that are related to depression, which include amino acid (phenylalanine), antioxidant properties, and anti-inflammatory effects.
3.1. Neurotrophic Factors

The complex biological properties of SBH consist of amino acids (phenylalanine, alanine, tyrosine, and valine), phenolic compounds, carbohydrates, organic acids, vitamins, minerals, lipids, and enzymes [139–143]. They have potential roles in the regulation of signaling pathways in depression development. The amino acid that is highlighted in this review is phenylalanine. Phenylalanine is an essential amino acid that needs to be ingested through diet since it is not naturally synthesized by the body [144]. It is an important amino acid for the synthesis of neurotransmitters and a precursor for dopamine and NA [87]. This can be related to the role of SBH as a prophylactic against depression, which is in line with the monoamine hypothesis. The monoamine hypothesis, which was explained earlier, stated low levels of neurotransmitters in depressed patients as well as in animal studies. Furthermore, the role of NA has been emphasized in attenuating microglial activation in the brain, thus inhibiting pro-inflammatory cytokines (inflammatory hypothesis) as well as enhancing the production of neurotrophic factors (neurotrophin hypothesis) for neurogenesis in the brain [145]. Moreover, neurotransmitters have been reported to enhance BDNF release in the brain [146]. Therefore, neurotransmitters and BDNF have a bilateral effect that can ameliorate depressive behavior. This indicates that the administration of SBH during depressive episodes could regulate the deficiency of neurotransmitters as well as BDNF, which is important to the neurological process. The regulation of the neurological process during depressive episodes would impede depressive behavior symptoms, such as sickness behavior, loss of motivation, and anhedonia [147–149].

3.2. Antioxidant

Stingless bee honey (SBH) has high levels of phenolic compounds compared to other honey [36,37,150]. Examples of phenolic acids in SBH are p-coumaric acid, gallic acid, caffeic acid, chrysin, and apigenin [28,150–152]. Antioxidant properties in honey have been reported to strongly correlate with phenolic compounds [153–155]. The color intensity of honey is also an indicator of antioxidant activity due to the presence of pigments such as carotenoids and flavonoids [156]. According to Kek and colleagues (2014), SBH has higher color intensity compared to Tualang, Gelam, Pineapple, Borneo, and commercial honey [36]. Antioxidants are important as scavengers in preventing oxidative stress that leads to DNA damage [157,158]. The brain is a highly susceptible organ to the elevation of oxidative stress due to its high oxygen demand [48,159,160]. Several researchers have reported the neuroprotective effect that resulted from the polyphenol content in honey [29]. These studies support SBH as a potential antidepressant since depression is also related to oxidative stress within the brain [41,161,162]. According to a study by Czarny and colleagues (2018), depressed patients had elevated reactive oxygen species (ROS) and nitrogen species (RNS) from oxidative DNA damage after depressive episodes [163].

Moreover, the relationship between oxidative stress and depression has been reviewed and discussed relating to its usage as a natural compound with antioxidant properties as a constituent of their polyphenols that can alleviate depression [41,164]. For example, antioxidant activity by p-coumaric acid has been identified in animal models of depression [48]. It has also been reported to show a neuroprotective response through increased levels of glutathione and superoxide dismutase that subsequently reduce oxidative stress capacity and neurotoxicity [165–167]. In addition to p-coumaric acid, chrysin also exhibited oxidative stress in the preclinical model of depression [168,169]. The properties of phenolic compounds proven to show efficacy based on both animal and human studies are displayed in Table 1.
The antioxidant activity in SBH can act as ROS scavengers that can regulate the mechanism of action to improve depression in patients. Antioxidants can cause prophylactic effects in depression since elevated ROS have been reported to affect BH4. In the inflammatory hypothesis, BH4 is briefly discussed as a cofactor for the biosynthesis of neurotransmitters 5HT, dopamine, and NA. The regulation of BH4 after the administration of SBH regulates neurotransmitters that consequently enhance mood, emotion, and behaviors after depressive episodes. Neurotransmitters are known for their role as modulators in brain activity. In addition, SBH possesses high intensity in terms of color pigment indicating the presence of flavonoids. Flavonoids found in honey activate the ERK and protein kinase B (PKB/Akt), leading to the activation of cAMP response element-binding protein (CREB), a transcription factor responsible for increasing BDNF expression [161]. Specifically, a gene expression analysis showed that BDNF and Itpr1 were affected following SBH treatments, and the results indicate that supplementation with SBH leads to specific upregulations of the gene expression tested and leads to an improvement in the depressive state [84].

### Table 1. Phenolic compounds that showed therapeutic effects on psychiatric and neurological disorders.

| Type           | Compounds   | Therapeutic Effects          |
|----------------|-------------|------------------------------|
| Phenolic acids | p-Coumaric acid | Anti-inflammatory, Antidepressant, Antioxidant |
|                | Gallic acid | [171] | [174–176] | [171,174] |
|                | Caffeic acid | [149] |
| Flavonoids     | Chrysin     | [168,169] | [177] | [168,169,177] |
|                | Apigenin    | [178–183] | [180,181,184–187] | [180,183,188] |
are also reports about the use of flavonoids in neurodegenerative disorders to regulate BDNF [189–192]. This evidence strongly suggests that SBH, which contains a high number of flavonoids, has the ability to enhance BDNF and regulate its levels as a determinant for antidepressant efficacy [91,93,193,194].

3.3. Anti-Inflammatory

Stingless bee honey (SBH) has been reported to possess anti-inflammatory properties [150,195]. According to a study by Ranneh and colleagues (2019), SBH has an anti-inflammatory effect in the LPS animal model. The etiology of depression has been discussed in depth through the inflammatory hypothesis perspective, especially with regard to how inflammation affects depression. Inflammation is known to activate the kynurenine pathway in depression [196]. This pathway causes cascade effects through the elevation of ROS and glutamate toxicity as well as a reduction of 5HT and BDNF [197–199]. Due to its anti-inflammatory properties, SBH can also regulate BDNF, hence alleviating depression symptoms. This is also essential due to its bilateral effect on the regulation of monoamine systems, which is important in ameliorating symptoms of depression [14,200].

The immune system is very sensitive to oxidative stress and with moderate exercise, immune functionality can be enhanced [48]. Exercise also has been recognized as a useful non-pharmacological strategy to improve the treatment of depression [201,202]. Relaxation responses significantly reduced the neuropsychological scores tested, decreased cortisol, decreased the trend of NGF, and increased BDNF levels [201]. BDNF binds to the tyrosine kinase β receptor (TrKβ) and activates the phosphoinositide 3-kinase and Akt pathway, which inhibits the activity of glycogen synthase kinase-3 β (GSK-3β) [202,203]. GSK-3β activity cleaves cadherin–β-catenin binding; therefore, GSK-3β inhibition stabilizes β-catenin, which regulates gene expression, synaptic plasticity, and neurogenesis, which in turn has antidepressant effects. A study using flavonoids found they seem to exert additional positive effects with exercise, where a combination of quercetin and exercise training exerted potent anti-tumor and anti-depressive effects through the suppression of inflammation and the upregulation of the BDNF/TrKβ/β-catenin axis in the prefrontal cortex of 1,2-dimethylhydrazine (DMH)-induced colorectal cancer-induced rats [202]. Thus, it is speculated that flavonoids in SBH express anti-inflammatory properties and are involved in the BDNF / TrKβ pathway; however, the specification of active possible chemotherapeutic modality needs further investigation. This statement supports the potential of SBH as an antidepressant due to its anti-inflammatory properties.

Recent studies on treatment resistance in depressed patients have related the condition to inflammation. Patients with treatment-resistant depression (TRD) have been reported to show dysregulated inflammatory activity compared to non-TRD patients [204,205]. They also exhibited increased levels of inflammatory cytokines (IL-6, IL8, TNF-α, CRP, and macrophage inflammatory protein-1 (MIP)-1 alpha) that resulted in poorer treatment outcomes [206]. Inflammatory cytokines are known as critical mediators in the inflammatory response that disrupt the signaling pathways or mechanisms of action of conventional antidepressants [204]. Therefore, anti-inflammatory treatments might be effective in preventing TRD in patients [207].

4. Conclusions

In conclusion, stingless bee honey could regulate the detrimental effects during or after depressive episodes that can lead to prophylactic effects. This review summarized how the amino acid (phenylalanine), antioxidant, and anti-inflammatory properties of SBH have the potential to control depression symptoms according to the etiology of depression—the monoamine, neurotrophin, and inflammatory hypotheses—through neurotrophic factors and its antioxidant and anti-inflammatory properties as shown in Figure 2.
Figure 2. Summary of the anti-depressive effects of SBH.

Our review reports the possible mechanisms of stingless bee honey pertaining to its antioxidant and anti-inflammatory properties, which contribute to its antidepressant properties. Follow-up studies are still required to comprehensively analyze the bioactive compound of SBH responsible for the underlying mechanisms as well as to investigate other possible pathways contributing to its anti-depressive effects.

Author Contributions: F.H.Z. and I.S. contributed to preparing the manuscript. M.Z.M. and N.S. contributed to reviewing the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by the Research Creativity and Management Office (RCMO), Universiti Sains Malaysia (USM), School of Medical Sciences, USM and Research University Incentive Grant with the Project Code: USM/1001/PPSP/8012252.

Institutional Review Board Statement: Ethical review and approval were waived for this study due to the study being a review of currently available literature.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Knol, M.J.; Twisk, J.W.; Beekman, A.T.; Heine, R.J.; Snoek, F.J.; Pouwer, F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006, 49, 837. [CrossRef] [PubMed]
2. Mauskopf, J.A.; Simon, G.E.; Kalsekar, A.; Nimsch, C.; Dunayevich, E.; Cameron, A. Nonresponse, partial response, and failure to achieve remission: Humanistic and cost burden in major depressive disorder. Depress. Anxiety 2009, 26, 83–97. [CrossRef] [PubMed]
3. Sousa, R.D.D.; Rodrigues, A.M.; Gregório, M.J.; Branco, J.D.C.; Gouveia, M.J.; Canhão, H.; Dias, S.S. Anxiety and depression in the Portuguese older adults: Prevalence and associated factors. Front. Med. 2017, 4, 196. [CrossRef]
4. Cohn, D.W.H.; Kinoshita, D.; Palermo-Neto, J. Antidepressants prevent hierarchy destabilization induced by lipopolysaccharide administration in mice: A neurobiological approach to depression. Ann. N. Y. Acad. Sci. 2012, 1262, 67–73. [CrossRef] [PubMed]
5. Zhu, X.L.; Chen, J.J.; Han, F.; Pan, C.; Zhuang, T.T.; Cai, Y.F.; Lu, Y.P. Novel antidepressant effects of Paenol alleviate neuronal injury with concomitant alterations in BDNF, Rac1 and RhoA levels in chronic unpredictable mild stress rats. Psychopharmacology 2018, 235, 2177–2191. [CrossRef] [PubMed]

6. Cai, S.; Huang, S.; Hao, W. New hypothesis and treatment targets of depression: An integrated view of key findings. Neurosci. Bull. 2015, 31, 61–74. [CrossRef] [PubMed]

7. Coppen, A. The biochemistry of affective disorders. Br. J. Psychiatry 1967, 113, 1237–1264. [CrossRef]

8. Schildkraut, J.J. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am. J. Psychiatry 1965, 122, 509–522. [CrossRef]

9. Bellmaker, R.H.; Agam, G. Major depressive disorder. N. Eng. J. Med. 2008, 358, 55–68. [CrossRef]

10. Hayley, S.; Poulter, M.O.; Merali, Z.; Anisman, H. The pathogenesis of clinical depression: Stressor-and cytokine-induced alterations of neuroplasticity. Neuroscience 2005, 135, 659–678. [CrossRef]

11. Hiles, S.A.; Baker, A.L.; de Malmanche, T.; Attia, J. A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: Exploring the causes of heterogeneity. Brain Behav. Immun. 2012, 26, 1180–1188. [CrossRef] [PubMed]

12. Duman, R.S.; Deyama, S.; Fogaça, M.V. Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants. Eur. J. Neurosci. 2021, 53, 126–139. [CrossRef]

13. Duman, R.S.; Heninger, G.R.; Nestler, E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54, 597–606. [CrossRef]

14. Kharade, S.M.; Gumate, D.S.; Naikwade, D. A Review: Hypothesis of Depression and Role of Antidepressant Drugs. Depression 2010, 15, 17.

15. Delgado, P.L. How antidepressants help depression: Mechanisms of action and clinical response. J. Clin. Psychiatry 2004, 65, 25–30.

16. Taylor, C.; Fricker, A.D.; Devi, L.A.; Gomes, I. Mechanisms of action of antidepressants: From neurotransmitter systems to signaling pathways. Cell. Signal. 2005, 17, 549–557. [CrossRef] [PubMed]

17. Masand, P.S.; Gupta, S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann. Clin. Psychiatry 2002, 14, 175–182. [CrossRef]

18. Schweitzer, I.; Maguire, K.; Ng, C. Sexual side-effects of contemporary antidepressants. Aust. N. Z. J. Psychiatry 2009, 43, 795–808. [CrossRef]

19. Mihaljević-Peleš, A.; Šagud, M.; Bajs Janović, M.; Kudlek Mikulić, S.; Jevtović, S. Do we need new therapeutic strategies for depression? Psychiatr. Danub. 2011, 23, 300–301. [PubMed]

20. Bet, P.M.; Hugtenburg, J.G.; Penninx, B.W.; Hoogendijk, W.J. Side effects of antidepressants during long-term use in a naturalistic setting. Eur. Neuropsychopharmacol. 2013, 23, 1443–1451. [CrossRef]

21. Richelson, E. Multi-modality: A new approach for the treatment of major depressive disorder. Int. J. Neuropsychopharmacol. 2013, 16, 1433–1442. [CrossRef] [PubMed]

22. Sharma, T.; Guski, L.S.; Freund, N.; Getzsche, P.C. Suicidality and aggression during antidepressant treatment: Systematic review and meta-analyses based on clinical study reports. BMJ 2016, 352, i65. [CrossRef] [PubMed]

23. Crisafulli, C.; Fabbri, C.; Porcelli, S.; Drago, A.; Spinà, E.; De Ronchi, D.; Serretti, A. Pharmacogenetics of antidepressants. Front. Pharmacol. 2011, 2, 6. [CrossRef]

24. Ruhé, H.G.; van Rooijen, G.; Spijker, J.; Peeters, F.P.; Schene, A.H. Staging methods for treatment resistant depression. A systematic review. J. Affect. Disord. 2012, 137, 35–45. [CrossRef]

25. Chiu, C.H.; Chyau, C.C.; Chen, C.C.; Lee, L.Y.; Chen, W.P.; Liu, J.L.; Lin, W.H.; Meng, M.C. Erinacine A-enriched Hericium erinaceus mycelium produces antidepressant-like effects through modulating BDNF/PI3K/Akt/GSK-3β signaling in mice. Int. J. Mol. Sci. 2018, 19, 341. [CrossRef]

26. Manoso, L.M.; Moretti, M.; Ribeiro, C.M.; Gonçalves, F.M.; Leal, R.B.; Rodrigues, A.L.S. Antidepressant-like effect of zinc is dependent on signaling pathways implicated in BDNF modulation. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2015, 59, 59–67.

27. Ali, S.S.; Abd El Wahab, M.G.; Ayoub, N.N.; Sulaiman, M. The antidepressant-like effect of Ocimum basilicum in an animal model of depression. Biotech. Histochem. 2017, 92, 390–401. [CrossRef]

28. Eregjuwa, O.O.; Sulaiman, S.A.; Ab Wahab, M.S. Honey: A novel antioxidant. Molecules 2012, 17, 4400–4423. [CrossRef]

29. Mijanur Rahman, M.; Gan, S.H.; Khalil, M. Neurological effects of honey: Current and future prospects. Evid.-Based Complement. Altern. Med. 2014, 2014, 958721. [CrossRef]

30. Münstedt, K.; Voss, B.; Kullmer, U.; Schneider, U.; Hübner, J. Bee pollen and honey for the alleviation of hot flushes and other menopausal symptoms in breast cancer patients. Mol. Clin. Oncol. 2015, 3, 869–874. [CrossRef]

31. Abd Wahab, M.S.; Othman, N.; Othman, N.H.I.; Jamari, A.A.; Ali, A.A. Exploring the use of and perceptions about honey as complementary and alternative medicine among the general public in the state of Selangor, Malaysia. J. Appl. Pharm. Sci. 2017, 7, 144–150.

32. Fatima, I.J.; Ab, M.H.; Salwani, I.; Lavaniya, M. Physicochemical characteristics of Malaysian stingless bee honey from trigona species. IJIM Med. J. Malays. 2018, 17, 187–191.

33. Roowi, S.; Muhamad, S.A.; Sipon, H.; Jaaflar, M.; Daud, M.; Hisham, N.; Othman, R. Asid fenolik bebas dalam madu kelulut. Bul. Teknol. MARDJ 2012, 2, 145–147.
34. Biswa, R.; Sarkar, A.; Khewa, S.S. Ethnomedicinal uses of honey of stingless bee by Nepali community of Darjeeling foothills of West Bengal, India. *Indian J. Tradit. Knowl.* 2017, 16, 648–653.

35. Özbalci, B.; Boyacı, I.H.; Topçu, A.; Kadılar, C.; Tamer, U. Rapid analysis of sugars in honey by processing Raman spectrum using chemometric methods and artificial neural networks. *Food Chem.* 2013, 136, 1444–1452. [CrossRef]

36. Kek, S.P.; Chin, N.L.; Yusof, Y.A.; Tan, S.W.; Chua, L.S. Total phenolic contents and colour intensity of Malaysian honeys from the Apis spp. and Trigona spp. bees. *Agric. Agric. Sci. Procedia* 2014, 2, 150–155.

37. Biluca, F.C.; Della Betta, F.; de Oliveira, G.P.; Pereira, L.M.; Gonzaga, L.V.; Costa, A.C.O.; Fett, R. 5-HMF and carbohydrates content in stingless bee honey by CE before and after thermal treatment. *Food Chem.* 2014, 159, 244–249. [CrossRef]

38. Sun, J.; Wang, H.; Liu, B.; Shi, W.; Shi, J.; Zhang, Z.; Xing, J. Rutin attenuates H2O2-induced oxidative damage and apoptosis in Leydig cells by activating PI3K/Akt signal pathways. *Biomed. Pharmacother.* 2017, 88, 500–506. [CrossRef]

39. Kanimozhi, S.; Bhavani, P.; Subramanian, P. Influence of the flavonoid, quercetin on antioxidant status, lipid peroxidation and histopathological changes in hyperammonemic rats. *Indian J. Clin. Biochem.* 2017, 32, 275–284. [CrossRef]

40. Nutt, D.J. Relationship of neurotransmitters to the symptoms of major depressive disorder. *J. Clin. Psychiatry* 2008, 69, 4–7.

41. Zhang, Z.; Deng, T.; Wu, M.; Zhu, A.; Zhu, G. Botanicals as modulators of depression and mechanisms involved. *Chin. Med.* 2019, 14, 24. [CrossRef] [PubMed]

42. Südhof, T.C. The cell biology of synapse formation. *J. Cell Biol.* 2021, 220, e202103052. [CrossRef] [PubMed]

43. Edmondson, D.E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Structure and mechanism of monoamine oxidase. *Curr. Med. Chem.* 2004, 11, 1983–1993. [CrossRef]

44. Kulkarni, S.K.; Dhir, A.; Akula, K.K. Potentials of curcumin as an antidepressant. *Sci. World J.* 2012, 2012, 1–9. [CrossRef]

45. Lee, M.; Schwab, C.; Mcgeer, P.L. Astrocytes are GABAergic cells that modulate microglial activity. *Neurochem. Res.* 2005, 30, 1066–1074. [CrossRef]

46. Wichers, M.; Maes, M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. *J. Neurosci.* 2003, 23, 87–93. [CrossRef]

47. Pletscher, A. The discovery of antidepressants: A winding path. *Experientia* 1991, 47, 4–8. [CrossRef]

48. Radak, Z.; Marton, O.; Nagy, E.; Koltai, E.; Goto, S. The complex role of physical exercise and reactive oxygen species on brain. *Neurosci. Lett.* 2013, 541, 106–109. [CrossRef]

49. Lee, S.; Kim, H.B.; Hwang, E.S.; Kim, E.S.; Kim, S.S.; Jeon, T.D.; Song, M.C.; Lee, J.S.; Chung, M.C.; Maeng, S.; et al. Antidepressant-like effects of p-coumaric acid on LPS-induced depressive and inflammatory changes in rats. *Exp. Neurobiol.* 2018, 27, 189. [CrossRef]

50. Tunnicliff, G.; Malatynska, E. Central GABAergic systems and depressive illness. *Neurochem. Res.* 2009, 34, 965–976. [CrossRef]

51. Rupperecht, R.; Eser, D.; Zwanzger, P.; Möller, H.J. GABAA receptors as targets for novel anxiolytic drugs. *World J. Psychiatry* 2006, 7, 231–237. [CrossRef] [PubMed]

52. Sequeira, A.; Turecki, G. Genome wide gene expression studies in mood disorders. *Omics A J. Integr. Biol.* 2006, 10, 444–454. [CrossRef] [PubMed]

53. Sanacora, G.; Saricicek, A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol. *Disord.-Drug Targets (Former. Curr. Drug Targets-CNS Neurol. Disord.)* 2006, 6, 127–140. [CrossRef] [PubMed]

54. Lee, M.; Schwab, C.; Mcgeer, P.L. Astrocytes are GABAergic cells that modulate microglial activity. *Glia* 2011, 59, 152–165. [CrossRef]

55. Oeckinghaus, A.; Ghosh, S. The NF-κB family of transcription factors and its regulation. *Cold Spring Harb. Perspect. Biol.* 2009, 1, a000034. [CrossRef] [PubMed]

56. Norgaard, M.; Møller, M.B.; Mortensen, P.B.; Olesen, K.A.; Dueholm, M. Lifestyle and risk of depression: A population-based study of more than 4 million people. *Depress. Anxiety* 2010, 27, 208–215. [CrossRef] [PubMed]

57. Karin, M.; Greten, F.R. NF-κB: Linking inflammation and immunity to cancer development and progression. *Nat. Rev. Immunol.* 2005, 5, 749. [CrossRef]

58. Napetschnig, J.; Wu, H. Molecular basis of NF-κB signaling. *Annu. Rev. Biochem.* 2013, 82, 443–468. [CrossRef]

59. Yu, B.; Chang, J.; Liu, Y.; Li, J.; Kevork, K.; Al-Hezaimi, K.; Graves, D.T.; Park, N.H.; Wang, C.Y. Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-κB. *Nat. Med.* 2014, 20, 1009. [CrossRef]

60. FitzGerald, G.A. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. *Nat. Rev. Drug Discov.* 2003, 2, 879. [CrossRef]

61. Munhoz, C.D.; Lepsch, L.B.; Kawamoto, E.M.; Malta, M.B.; de Sá Lima, L.; Avellar, M.C.W.; Sapolsky, R.M.; Scavone, C. Chronic unpredictable stress exacerbates lipopolysaccharide-induced activation of nuclear factor-κB in the frontal cortex and hippocampus via glucocorticoid secretion. *J. Neurosci.* 2006, 26, 3813–3820. [CrossRef] [PubMed]

62. Miller, A.H.; Maletic, V.; Raison, C.L. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. *Biol. Psychiatry* 2009, 65, 732–741. [CrossRef] [PubMed]

63. Han, Q.Q.; Yu, J. Inflammation: A mechanism of depression? *Neurosci. Bull.* 2014, 30, 515–523. [CrossRef]

64. Llorens-Martín, M.; Jurado-Arjona, J.; Fuster-Matanzo, A.; Hernandez, F.; Rabano, A.; Avila, J. Peripherally triggered and GSK-3β-driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen. *Transl. Psychiatry* 2014, 4, e463. [CrossRef]

65. Norden, D.M.; McCarthy, D.O.; Bicer, S.; Devine, R.D.; Reiser, P.J.; Godbout, J.P.; Wold, L.E. Ibuprofen ameliorates fatigue-and depressive-like behavior in tumor-bearing mice. *Life Sci.* 2015, 143, 65–70. [CrossRef] [PubMed]
66. Koo, J.W.; Duman, R.S. IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 751–756. [CrossRef] [PubMed]
67. Dantzer, R.; O’Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelley, K.W. From inflammation to sickness and depression: When the immune system subjugates the brain. *Nat. Rev. Neurosci.* **2008**, *9*, 46. [CrossRef] [PubMed]
68. Pérez-Sánchez, G.; Becerril-Villanueva, E.; Arreola, R.; Martínez-Levy, G.; Hernández-Gutiérrez, M.E.; Velasco-Velásquez, M.A.; Álvarez-Herrera, S.; Cruz-Fuentes, C.; Palacios, L.; De La Peña, F.; et al. Inflammatory profiles in depressed adolescents treated with fluoxetine: An 8-week follow-up open study. *Mediat. Inflamm.* **2018**, *2018*, 4074051. [CrossRef]
69. Kasai, T.; Inada, K.; Takakuwa, T.; Yamada, Y.; Inoue, Y.; Shimamura, T.; Taniguchi, S.; Sato, S.; Wakabayashi, G.; Endo, S. Anti-inflammatory cytokine levels in patients with septic shock. *Res. Commun. Mol. Pathol. Pharmacol.* **1997**, *98*, 34–42.
70. Rubio-Perez, J.M.; Morillas-Ruiz, J.M. A Review: Inflammatory Process in Alzheimer’s Disease, Role of Cytokines. *Sci. World J.* **2012**, *2012*, 756357. [CrossRef]
71. Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctôt, K.L. A Meta-analysis of cytokines in major depression. *BioMed Res. Int.* **2014**, *67*, 446–457. [CrossRef] [PubMed]
72. Leighton, S.P.; Nerurkar, L.; Krishnadas, R.; Johnman, C.; Graham, G.J.; Cavanagh, J. Chemokines in depression in health and in inflammatory illness: A systematic review and meta-analysis. *Mol. Psychiatry* **2018**, *23*, 48. [CrossRef] [PubMed]
73. Duman, R.S.; Aghajanian, G.K. Synaptic dysfunction in depression: Potential therapeutic targets. *Science* **2012**, *338*, 68–72. [CrossRef] [PubMed]
74. Capuron, L.; Miller, A.H. Immune system to brain signaling: Neuropsychopharmacological implications. *Pharmacol. Ther.* **2011**, *130*, 226–238. [CrossRef] [PubMed]
75. Haroon, E.; Miller, A.H.; Sanacora, G. Inflammation, glutamate, and glia: A trio of trouble in mood disorders. *Neuropsychopharmacology* **2017**, *42*, 193. [CrossRef] [PubMed]
76. Park, S.E.; Dantzer, R.; Kelley, K.W.; McCusker, R.H. Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. *J. Neuroinflamm.* **2011**, *8*, 12. [CrossRef] [PubMed]
77. Dobos, N.; de Vries, E.F.; Kema, I.P.; Patas, K.; Prins, M.; Nijholt, I.M.; Dierckx, R.A.; Korf, J.; den Boer, J.A.; Luiten, P.G.; et al. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. *J. Alzheimer’s Dis.* **2012**, *28*, 905–915. [CrossRef]
78. Lawson, M.A.; Parrott, J.M.; McCusker, R.H.; Dantzer, R.; Kelley, K.W.; O’Connor, J.C. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. *J. Neuroinflamm.* **2013**, *10*, 875. [CrossRef]
79. Vancassel, S.; Capuron, L.; Castanon, N. Brain kynurenine and BH4 pathways: Relevance to the pathophysiology and treatment of inflammation-driven depressive symptoms. *Front. Neurosci.* **2018**, *12*, 499. [CrossRef]
80. Hestad, K.A.; Engedal, K.; Whist, J.E.; Farup, P.G. The relationships among tryptophan, kynurenine, indoleamine 2,3-dioxygenase, depression, and depressive-like syndromes. *Front. Psychol.* **2017**, *8*, 1561. [CrossRef]
81. O’connor, J.C.; Lawson, M.A.; Andre, C.; Moreau, M.; Lestage, J.; Castanon, N.; Kelley, K.W.; Dantzer, R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. *Mol. Psychiatry* **2009**, *14*, 511. [CrossRef]
82. Raison, C.L.; Dantzer, R.; Kelley, K.W.; Lawson, M.A.; Woolwine, B.J.; Vogt, G.; Spivie, J.R.; Saito, K.; Miller, A.H. CSF cytokine levels and pathological conditions. *Molecules* **2022**, *27*, 5091. [CrossRef] [PubMed]
83. Schwarcz, R.; Stone, T.W. The kynurenine pathway and the brain: Challenges, controversies and promises. *Mol. Psychiatry* **2017**, *112*, 237–247. [CrossRef] [PubMed]
84. Neurauter, G.; Schrocksnadel, K.; Scholl-Burgi, S.; Sperrer-Unterweger, B.; Schubert, C.; Ledochowski, M.; Fuchs, D. Chronic immune stimulation correlates with reduced phenylalanine turnover. *J. Inherit. Metab. Dis.* **2012**, *35*, 751–756. [CrossRef] [PubMed]
85. Koo, J.W.; Duman, R.S. Interleukin-1β is an essential mediator of the antineurogenic and anhedonic effects of stress. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 751–756. [CrossRef] [PubMed]
86. Mustafa, M.Z.; Zulkifi, F.N.; Fernandez, I.; Mariatuqtabiah, A.R.; Sangu, M.; Nor Azfa, J.; Mohamed, M.; Roslan, N. Stingless bee honey improves spatial memory in mice, probably associated with brain-derived neurotrophic factor (BDNF) and inositol 1, 4, 5-triphosphate receptor type 1 (Itpr1) genes. *Evid.-Based Complement. Altern. Med.* **2019**, *2019*, 8258307. [CrossRef]
87. Lu, L.; Ben, X.; Xiao, L.; Peng, M.; Zhang, Y. AMP-activated protein kinase activation in mediating phenylalanine-induced neurotoxicity in experimental models of phenylketonuria. *J. Inherit. Metab. Dis.* **2018**, *41*, 679–687. [CrossRef] [PubMed]
88. Strasser, B.; Sperner-Unterweger, B.; Fuchs, D.; Gostner, J.M. Mechanisms of inflammation-associated depression: Immune influences on tryptophan and phenylalanine metabolisms. *Inflamm.-Assoc. Depress. Evid.-Based Complement. Altern. Med.* **2013**, *12*, 499. [CrossRef]
89. Neurauter, G.; Schrocksnadel, K.; Scholl-Burgi, S.; Sperrer-Unterweger, B.; Schubert, C.; Ledochowski, M.; Fuchs, D. Chronic immune stimulation correlates with reduced phenylalanine turnover. *Curr. Drug Metab.* **2008**, *9*, 622–627. [CrossRef] [PubMed]
90. Duman, R.S.; Li, N. A neurotrophic hypothesis of depression: Role of synaptogenesis in the actions of NMDA receptor antagonists. *Neuropharmacology* **2012**, *68*, 875. [CrossRef]
91. Begni, V.; Riva, M.A.; Cattaneo, A. Cellular and molecular mechanisms of the brain-derived neurotrophic factor in physiological and pathological conditions. *Clin. Sci.* **2017**, *131*, 123–138. [CrossRef]
92. Galea, R.; Cassar, D. Brain-Derived Neurotrophic Factor—Major Depressive Disorder and Suicide. *Open Access Libr. J.* 2019, 6, e5106. [CrossRef] 

93. Björkholm, C.; Monteggia, L.M. BDNF—a key transducer of antidepressant effects. *Neuropsychopharmacology* 2016, 102, 72–79. [CrossRef] [PubMed] 

94. Lee, B.H.; Kim, Y.K. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. *Psychiatry Investig.* 2010, 7, 231. [CrossRef] [PubMed] 

95. Park, H.; Poo, M.M. Neurotrophin regulation of neural circuit development and function. *Nat. Rev. Neurosci.* 2013, 14, 7. [CrossRef] [PubMed] 

96. Lu, B.; Nagappan, G.; Lu, Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. *Neurotrophic Factors* 2014, 220, 223–250. 

97. Zheleznyakova, G.Y.; Cao, H.; Schiöth, H.B. BDNF DNA methylation changes as a biomarker of psychiatric disorders: Literature review and open access database analysis. *Behav. Brain Funct.* 2016, 12, 17. [CrossRef] [PubMed] 

98. Altar, C.A. Neurotrophins and depression. *Trends Pharmacol. Sci.* 1999, 20, 59–62. [CrossRef] 

99. Numakawa, T.; Odaka, H.; Adachi, N. Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases. *Int. J. Mol. Sci.* 2018, 19, 3650. [CrossRef] 

100. Liu, B.B.; Luo, L.; Liu, X.L.; Geng, D.; Liu, Q.; Yi, L.T. 7-Chlorokynurenic acid (7-CTKA) produces rapid antidepressant-like effects: Through regulating hippocampal microRNA expressions involved in TrkB-ERK/Akt signaling pathways in mice exposed to chronic unpredictable mild stress. *Psychopharmacology* 2015, 232, 541–550. [CrossRef] [PubMed] 

101. Yan, T.; He, B.; Wan, S.; Xu, M.; Yang, H.; Xiao, F.; Bi, K.; Jia, Y. Antidepressant-like effects and cognitive enhancement of Schisandra chinensis in chronic unpredictable mild stress mice and its related mechanism. *Sci. Rep.* 2017, 7, 6903. [CrossRef] [PubMed] 

102. Zhang, X.; Song, Y.; Bao, T.; Yu, M.; Xu, M.; Guo, Y.; Wang, Y.; Zhang, C.; Zhao, B. Antidepressant-like effects of acupuncture involved the ERK signaling pathway in rats. *BMC Complement. Altern. Med.* 2016, 16, 380. [CrossRef] [PubMed] 

103. Chen, X.Q.; Li, C.F.; Chen, S.J.; Liang, W.N.; Wang, M.; Wang, S.S.; Dong, S.Q.; Yi, L.T.; Li, C.D. The antidepressant-like effects of Chaihu Shugan San: Dependent on the hippocampal BDNF-TrkB-Akt signaling activation in perinatal depression-like rats. *Biomed. Pharmacother.* 2018, 105, 45–52. [CrossRef] 

104. Man, H.Y.; Wang, Q.; Lu, W.Y.; Ju, W.; Ahmadian, G.; Liu, L.; D'Souza, S.; Wong, T.P.; Taghibiglou, C.; Lu, J.; et al. Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons. *Neuron* 2003, 38, 611–624. [CrossRef] 

105. Stornetta, R.L.; Zhu, J.J. Ras and Rap signaling in synaptic plasticity and mental disorders. *Neuroscientist* 2011, 17, 54–78. [CrossRef] 

106. Duman, R.S.; Monteggia, L.M. A neurotrophic model for stress-related mood disorders. *Biol. Psychiatry* 2006, 59, 1116–1127. [CrossRef] 

107. Duman, R.S.; Voleti, B. Signaling pathways underlying the pathophysiology and treatment of depression: Novel mechanisms for rapid-acting agents. *Trends Neurosci.* 2012, 35, 47–56. [CrossRef] 

108. Tomita, H.; Ziegler, M.E.; Kim, H.B.; Evans, S.J.; Choudary, PV.; Li, J.Z.; Meng, F.; Dai, M.; Neal, C.R.; Myers, R.M.; et al. G protein-linked signaling pathways in bipolar and major depressive disorders. *Front. Genet.* 2013, 4, 297. [CrossRef] 

109. Plattner, F.; Hayashii, K.; Hernández, A.; Benavides, D.R.; Tassin, T.C.; Tan, C.; Day, J.; Fina, M.W.; Yuen, E.Y.; Yan, Z.; et al. The role of ventral striatal CaM-P signaling in stress-induced behaviors. *Nat. Neurosci.* 2015, 18, 1094. [CrossRef] [PubMed] 

110. Duman, R.S.; Aghajanian, G.K.; Sanacora, G.; Krystal, J.H. Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. *Nat. Med.* 2016, 22, 238. [CrossRef] [PubMed] 

111. Cramer, S.C.; Sur, M.; Dobkin, B.H.; O’Brien, C.; Sanger, T.D.; Trojanowsky, J.Q.; Rumsey, J.M.; Hicks, R.; Cameron, J.; Chen, D.; et al. Harnessing neuroplasticity for clinical applications. *Brain* 2011, 134, 1591–1609. [CrossRef] [PubMed] 

112. Levy, M.J.; Boule, F.; Steinbusch, H.W.; van den Hove, D.L.; Kenis, G.; Lanfumey, L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. *Psychopharmacology* 2018, 235, 2195–2220. [CrossRef] [PubMed] 

113. Vilar, M.; Mira, H. Regulation of neurogenesis by neurotrophins during adulthood: Expected and unexpected roles. *Brain Sci.* 2016, 6, 238. [CrossRef] [PubMed] 

114. Seib, D.R.; Martin-Villalba, A. Neurogenesis in the normal ageing hippocampus: A mini-review. *Gerontology* 2015, 61, 327–335. [CrossRef] 

115. Eisch, A.J.; Petrlik, D. Depression and hippocampal neurogenesis: A road to remission? *Science* 2012, 338, 72–75. [CrossRef] 

116. Bremer, J.D.; Narayan, M.; Anderson, E.R.; Staib, L.H.; Miller, H.L.; Charney, D.S. Hippocampal volume reduction in major depression. *Am. J. Psychiatry* 2000, 157, 115–118. [CrossRef] 

117. Cole, J.; Costaferda, S.G.; McGuffin, P.; Fu, C.H. Hippocampal atrophy in first episode depression: A meta-analysis of magnetic resonance imaging studies. *J. Affect. Disord.* 2011, 134, 483–487. [CrossRef]
175. Pemminati, S.; Shetty, B.S.; Gopalakrishna, H.N.; Bethi, Y.; Rao, D.; Udaykumar, J.; Rai, A.; Shenoy, A.K. Evaluation of antidepressant activity of gallic acid in mice. *Res. J. Pharm. Biol. Chem. Sci.* 2014, 5, 575–580.

176. Can, O.D.; Turan, N.; Özkan, U.D.; Öztürk, Y. Antidepressant-like effect of gallic acid in mice: Dual involvement of serotonergic and catecholaminergic systems. *Life Sci.* 2017, 190, 110–117. [CrossRef] [PubMed]

177. Bortolotto, V.C.; Pinheiro, E.C.; Araujo, S.M.; Poetini, M.R.; Bertolazi, B.S.; Mariane Trindade de Paula, M.; Meichtry, L.B.; Polet de Almeida, F.; Shanda de Freitas, C.; Jesse, C.R.; et al. Chrysin reverses the depressive-like behavior induced by hypothyroidism in female mice by regulating hippocampal serotonin and dopamine. *Eur. J. Pharmacol.* 2018, 822, 78–84. [CrossRef] [PubMed]

178. Rezai-Zadeh, K.; Ehrhart, J.; Bai, Y.; Sanberg, P.R.; Bickford, P.; Ten, J.; Shytle, R.D. Apigenin and luteolin modulate microglial activation via inhibition of STAI-induced CD40 expression. *J. Neuroinflamm.* 2008, 5, 1–10. [CrossRef] [PubMed]

179. Shahamat, Z.; Abbasi-Maleki, S.; Motamed, S.M. Evaluation of antidepressant-like effects of aqueous and ethanolic extracts of Pimpinella anisum fruit in mice. *Avicenna J. Phytopharm.* 2016, 6, 322. [PubMed]

180. Li, R.; Wang, X.; Qin, T.; Qu, R.; Ma, S. Apigenin ameliorates chronic mild stress-induced depressive behavior by inhibiting interleukin-1β production and NLRP3 inflammasome activation in the rat brain. *Behav. Brain Res.* 2016, 296, 318–325. [CrossRef] [PubMed]

181. Zhang, X.; Bu, H.; Jiang, Y.; Sun, G.; Jiang, R.; Huang, X.; Duan, H.; Huang, Z.; Wu, Q. The antidepressant effects of apigenin are associated with the promotion of autophagy via the mTOR/AMPK/ULK1 pathway. *Mol. Med. Rep.* 2019, 20, 2867–2874. [CrossRef]

182. Balez, R.; Steiner, N.; Engel, M.; Muñoz, S.S.; Lum, J.S.; Wu, Y.; Wang, D.; Vallotton, P.; Sachdev, P.; O’Connor, M.; et al. Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer’s disease. *Sci. Rep.* 2016, 6, 31450. [CrossRef] [PubMed]

183. Kashyap, D.; Sharma, A.; Tuli, H.S.; Sak, K.; Garg, V.K.; Buttar, H.S.; Setzer, W.N.; Sethi, G. Apigenin: A natural bioactive flavone-type molecule with promising therapeutic function. *J. Funct. Foods* 2018, 48, 457–471. [CrossRef]

184. Nakazawa, T.; Yasuda, T.; Ueda, J.; Ohsawa, K. Antidepressant-like effects of apigenin and 2,4,5-trimethoxycinnamic acid from Perilla frutescens in the forced swimming test. *Biol. Pharm. Bull.* 2003, 26, 474–480. [CrossRef]

185. Yi, L.T.; Li, J.M.; Li, Y.C.; Pan, Y.; Xu, Q.; Kong, L.D. Antidepressant-like behavioral and neurochemical effects of the citrus-flavone-type molecule with promising therapeutic function. *J. Funct. Foods* 2018, 48, 457–471. [CrossRef]

186. Li, R.; Zhao, D.; Qu, R.; Fu, Q.; Ma, S. The effects of apigenin on lipopolysaccharide-induced depressive-like behavior in mice. *Neurosci. Lett.* 2015, 594, 17–22. [CrossRef] [PubMed]

187. Weng, L.; Guo, X.; Li, Y.; Yang, X.; Han, Y. Apigenin reverses depression-like behavior induced by chronic corticosterone treatment in mice. *Eur. J. Pharmacol.* 2016, 774, 50–54. [CrossRef] [PubMed]

188. Anusha, C.; Sumathi, T.; Joseph, L.D. Protective role of apigenin on rotenone induced rat model of Parkinson’s disease: Suppression of neuroinflammation and oxidative stress mediated apoptosis. *Chem. Biol. Interact.* 2017, 269, 67–79. [CrossRef] [PubMed]

189. Jang, S.W.; Liu, X.; Yepes, M.; Shepherd, K.R.; Miller, G.W.; Liu, Y.; Wilson, W.D.; Xiao, G.; Blanchi, B.; Sun, Y.E.; et al. A selective TrkB agonist with potent neurotrophic activities by 7, 8-dihydroxyflavone. *Proc. Natl. Acad. Sci. USA* 2010, 107, 2687–2692. [CrossRef] [PubMed]

190. Oboh, G.; Ogunsuyi, O.B.; Ogundadejo, M.D.; Adefegha, S.A. Influence of gallic acid on α-amylase and α-glucosidase inhibitory properties of acarbose. *J. Food Drug Anal.* 2016, 24, 627–634. [CrossRef]

191. Wurzelmann, M.; Romeika, J.; Sun, D. Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury. *Neural Regen. Res.* 2017, 12, 7.

192. Rahvar, M.; Owji, A.A.; Mashayekhi, F.J. Effect of quercetin on the brain-derived neurotrophic factor gene expression in the rat brain. *Brasil. Lek. Listy* 2018, 119, 28–31. [CrossRef]

193. Caviedes, A.; Lafourcade, C.; Soto, C.; Wynene, U. BDNF/NF-kB Signaling in the Neurobiology of Depression. *Curr. Pharm. Des.* 2017, 23, 3154–3163. [CrossRef] [PubMed]

194. Kowiański, P.; Lietzau, G.; Czuba, E.; Waśkow, M.; Steliga, A.; Moryś, J. BDNF: A key factor with multipotential impact on brain signaling and synaptic plasticity. *Cell. Mol. Neurobiol.* 2018, 38, 579–593. [CrossRef] [PubMed]

195. Borsato, D.M.; Prudente, A.S.; Doell-Boscardin, P.M.; Borsato, A.V.; Luz, C.F.; Maia, B.H.; Cabrini, D.A.; Otuki, M.F.; Miguel, M.D.; Farago, P.V.; et al. Topical anti-inflammatory activity of a monofloral honey of Mimosa scabrella provided by Melipona marginata during winter in Southern Brazil. *Food Res. J. Pharm. Biol. Chem. Sci.* 2018, 36, 594, 3154–3163. [CrossRef] [PubMed]

196. Kaster, M.P.; Gadotti, V.M.; Calixto, J.B.; Santos, A.R.; Rodrigues, A.L.S. Depressive-like behavior induced by tumor necrosis factor-α in mice. *Neuropharmacology* 2012, 60, 419–426. [CrossRef]

197. Tavares, R.G.; Schmidt, A.P.; Abud, J.; Tasca, C.I.; Souza, D.O. In vivo quinolinic acid increases synaptosomal glutamate release in rats: Reversal by guanosine. *Neurochem. Res.* 2005, 30, 439–444. [CrossRef]

198. McNally, L.; Bhagwagar, Z.; Hannestad, J. Inflammation, glutamate, and glia in depression: A literature review. *CNS Spectr.* 2008, 13, 501–510. [CrossRef]

199. Dantzer, R.; O’Connor, J.C.; Lawrence, W.C.; Dalton, P.M.; Kelley, K.W. Inflammation-associated depression: From serotonin to kynurenine. *Psychoneuroendocrinology* 2011, 36, 426–436. [CrossRef]

200. Yu, S.; Holsboer, F.; Almeida, O.F. Neuronal actions of glucocorticoids: Focus on depression. *J. Steroid Biochem. Mol. Biol.* 2008, 108, 300–309. [CrossRef]
201. Zappella, M.; Biamonte, F.; Balzamino, B.O.; Manieri, R.; Cortes, M.; Santucci, D.; Di Stasio, E.; Rizzuto, M.; Micera, A. Relaxation Response in Stressed Volunteers: Psychometric Tests and Neurotrophin Changes in Biological Fluids. *Front. Psychiatry* 2021, 12, 790. [CrossRef]

202. Sadighparvar, S.; Darband, S.G.; Yousefi, B.; Kaviani, M.; Ghaderi-Pakdel, F.; Mihanfar, A.; Babaei, G.; Mobaraki, K.; Majidinia, M. Combination of quercetin and exercise training attenuates depression in rats with 1,2-dimethylhydrazine-induced colorectal cancer: Possible involvement of inflammation and BDNF signalling. *Exp. Physiol.* 2020, 105, 1598–1609. [CrossRef] [PubMed]

203. Zhang, J.C.; Yao, W.; Hashimoto, K. Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets. *Curr. Neuropharmacol.* 2016, 14, 721–731. [CrossRef] [PubMed]

204. Raison, C.L.; Felger, J.C.; Miller, A.H. Inflammation and treatment resistance in major depression: A perfect storm. *Psychiatr. Times* 2013, 30, 17.

205. Strawbridge, R.; Young, A.H.; Cleare, A.J. Inflammation as a marker of clinical response to treatment: A focus on treatment-resistant depression. In *Inflammation and Immunity in Depression*; Academic Press: Cambridge, MA, USA, 2018; pp. 473–487.

206. Strawbridge, R.; Hodsoll, J.; Powell, T.R.; Hotopf, M.; Hatch, S.L.; Breen, G.; Cleare, A.J. Inflammatory profiles of severe treatment-resistant depression. *J. Affect. Disord.* 2019, 246, 42–51. [CrossRef] [PubMed]

207. Husain, M.I.; Strawbridge, R.; Stokes, P.R.; Young, A.H. Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis. *J. Psychopharmacol.* 2017, 31, 1137–1148. [CrossRef]